[go: up one dir, main page]

LV10190A - Panemiens alkoholisma arstesanai ar naimifinu - Google Patents

Panemiens alkoholisma arstesanai ar naimifinu

Info

Publication number
LV10190A
LV10190A LV931052A LV931052A LV10190A LV 10190 A LV10190 A LV 10190A LV 931052 A LV931052 A LV 931052A LV 931052 A LV931052 A LV 931052A LV 10190 A LV10190 A LV 10190A
Authority
LV
Latvia
Prior art keywords
naimifin
drop
alcoholism treatment
alcoholism
treatment
Prior art date
Application number
LV931052A
Other languages
English (en)
Other versions
LV10190B (en
Inventor
John D Sinclair
Harry Scheinin
Risto Lammintausta
Original Assignee
Alko Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alko Ltd filed Critical Alko Ltd
Publication of LV10190A publication Critical patent/LV10190A/lv
Publication of LV10190B publication Critical patent/LV10190B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LVP-93-1052A 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene LV10190B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene
PCT/US1991/003241 WO1991018605A1 (en) 1990-06-04 1991-05-10 Method for treating alcoholism with nalmefene

Publications (2)

Publication Number Publication Date
LV10190A true LV10190A (lv) 1994-10-20
LV10190B LV10190B (en) 1995-06-20

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-93-1052A LV10190B (en) 1990-06-04 1993-08-31 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (lv)
EP (1) EP0531415B1 (lv)
JP (1) JP3059213B2 (lv)
AT (1) ATE145329T1 (lv)
AU (1) AU642748B2 (lv)
CA (1) CA2084519C (lv)
DE (1) DE69123247T2 (lv)
DK (1) DK0531415T3 (lv)
ES (1) ES2097209T3 (lv)
FI (1) FI925513A0 (lv)
GR (1) GR3022289T3 (lv)
HU (1) HU210637B (lv)
IE (1) IE77333B1 (lv)
LT (1) LT3893B (lv)
LV (1) LV10190B (lv)
NZ (1) NZ238391A (lv)
RU (1) RU2090190C1 (lv)
WO (1) WO1991018605A1 (lv)
ZA (1) ZA914185B (lv)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
CA2392510A1 (en) * 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
RU2227004C2 (ru) * 2000-06-16 2004-04-20 Писаренко Фаля Юрьевич Способ лечения наркологической зависимости
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP4736323B2 (ja) * 2001-07-13 2011-07-27 アークレイ株式会社 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
PL368612A1 (en) * 2001-08-14 2005-04-04 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
RU2200556C1 (ru) * 2001-12-05 2003-03-20 Северцев Владимир Алексеевич Лекарственная форма налтрексона
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
EP1610791B1 (en) * 2003-03-31 2011-02-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20050038062A1 (en) * 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
MX2008016372A (es) * 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
RS52041B (sr) * 2008-04-24 2012-04-30 Janssen Pharmaceutica N.V. Prolekovi nalmefena
AU2009239927B2 (en) * 2008-04-24 2014-03-13 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
RU2393864C1 (ru) * 2008-12-29 2010-07-10 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и опиоидной наркомании
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
US20140005216A1 (en) * 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
SG10201809280PA (en) * 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
RU2717677C1 (ru) * 2016-04-22 2020-03-25 Тайваньж Фармасьютикалс Со., Лтд. Налмефен, налтрексон или их производные для применения в лечении (не)алкогольного стеатогепатита или неалкогольной жировой болезни печени

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
HU210637B (en) 1995-06-28
NZ238391A (en) 1997-06-24
HUT65523A (en) 1994-06-28
ES2097209T3 (es) 1997-04-01
RU2090190C1 (ru) 1997-09-20
IE77333B1 (en) 1997-12-03
CA2084519C (en) 1999-02-09
ATE145329T1 (de) 1996-12-15
CA2084519A1 (en) 1991-12-05
LV10190B (en) 1995-06-20
LTIP1486A (en) 1995-09-25
HU9203835D0 (en) 1993-03-29
AU7974091A (en) 1991-12-31
GR3022289T3 (en) 1997-04-30
DK0531415T3 (da) 1996-12-09
ZA914185B (en) 1992-07-29
AU642748B2 (en) 1993-10-28
WO1991018605A1 (en) 1991-12-12
IE911888A1 (en) 1991-12-04
EP0531415A1 (en) 1993-03-17
EP0531415B1 (en) 1996-11-20
US5086058A (en) 1992-02-04
FI925513L (fi) 1992-12-04
FI925513A7 (fi) 1992-12-04
JP3059213B2 (ja) 2000-07-04
JPH06506665A (ja) 1994-07-28
LT3893B (en) 1996-04-25
FI925513A0 (fi) 1992-12-04
DE69123247T2 (de) 1998-01-15
DE69123247D1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
LV10190A (lv) Panemiens alkoholisma arstesanai ar naimifinu
RU92016403A (ru) Способ лечения алкоголизма налмефеном
MXPA99001239A (es) Proceso mejorado para la produccion de bebidas alcoholicas que utilizan semilla de malta.
NO963785L (no) Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
EE9600187A (et) Filter jookide, peamiselt kohvi jaoks ja meetod selle tootmiseks
DE59308000D1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
AU3397795A (en) A method for production of ethyl alcohol
DE59004541D1 (de) Verfahren zum Vermindern des Alkoholgehaltes alkoholischer Getränke.
DE69533988D1 (de) Verfahren zum blokieren von sec-rezeptoren
NO914885D0 (no) Fremgangsmaate for utvinning av mikrobiologisk produsert chymosin
ZA9472B (en) Process for producing low molecular-weight poly-1-olefins.
FI940969L (fi) Menetelmä vedenerottuvuuden parantamiseksi mäntyöljyn valmistusprosessissa sekä menetelmä mäntyöljyn valmistamiseksi
GR3015586T3 (en) Process for producing fuel oil and gas by cracking waste rubber.
ES2121554A1 (es) Procedimiento de obtencion de 14-hidroximorfinas mediante fotooxidacion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
DK0805847T3 (da) Alkoholholdig instant-drikkeblanding, dens fremstilling og anvendelse
HUT69760A (en) Process for the preparation of in alfa-position by alkyl group substituted aldehyde
AU5102490A (en) Process of treating alcoholic beverages by vapor-arbitrated pervaporisation
GR3024442T3 (en) Method to purify streptolysin o, intact streptolysin o obtainable by this method and its use
MD188B2 (ro) Procedeu de producere a extractului pentru bauturi alcoolice
FI891652A7 (fi) Menetelmä proteiinien valmistamiseksi, joiden N-terminaali alkaa proliinilla
DE69410898D1 (de) Verfahren zur herstellung von n,n,-disubstituiertem aminophenol
NO950978D0 (no) Polyolefinbasert pigmentert blanding, samt fremgangsmåte for fremstilling av tilformede gjenstander med utgangspunkt i blandingen
HUT64765A (en) Method for producing oxa-bicyclo[2.2.1] heptane-2,3-dimethanol-derivatives
AU2767192A (en) Process for producing chloroisocyanurates with hypochlorous acid
KR900002724A (ko) 오징어를 이용한 술병의 제조방법